REBEC

Public trial

Study on the effects of cupping therapy on muscle recovery after exercise

Date of registration: 07/31/2026 ^(mm/dd/yyyy)
Last approval date : 07/31/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Glycemic response of fortified foods

Date of registration: 07/31/2026 ^(mm/dd/yyyy)
Last approval date : 07/31/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of cardiorespiratory and muscle-strengthening exercises on the health of people with Obesity

Date of registration: 07/31/2026 ^(mm/dd/yyyy)
Last approval date : 07/31/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of Pilates exercises on cellular health and quality of life in women with Endometriosis

Date of registration: 07/30/2026 ^(mm/dd/yyyy)
Last approval date : 07/30/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

360° virtual reality treatment for public speaking anxiety

Date of registration: 07/30/2026 ^(mm/dd/yyyy)
Last approval date : 07/30/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of Transcranial Stimulation and balance training in individuals with Parkinson: a randomized clinical trial

Date of registration: 07/11/2022 ^(mm/dd/yyyy)
Last approval date : 07/30/2026 ^(mm/dd/yyyy)
Last revision: 3

Study type:

Interventional

Evaluation of the physiotherapeutic prescription of green exercise for patients with Breast Cancer and chemotherapy-induced peripheral neuropathy (CIPN): A randomized controlled trial

Date of registration: 07/30/2026 ^(mm/dd/yyyy)
Last approval date : 07/30/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of electronic devices for measuring root canal length in primary teeth

Date of registration: 07/30/2026 ^(mm/dd/yyyy)
Last approval date : 07/30/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The use of Regenerating Gel in the treatment of Dental Densitivity in pediatric patients

Date of registration: 07/29/2026 ^(mm/dd/yyyy)
Last approval date : 07/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Virtual reality to train healthcare professionals in the care of children with Autism Spectrum Disorder

Date of registration: 07/29/2026 ^(mm/dd/yyyy)
Last approval date : 07/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Enamel cracks and the use of gingival barrier in dental bleaching

Date of registration: 07/29/2026 ^(mm/dd/yyyy)
Last approval date : 07/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Methylene blue Laser vs. blue LED in Biofilm control in difficult-to-heal wounds: a randomized clinical trial

Date of registration: 07/29/2026 ^(mm/dd/yyyy)
Last approval date : 07/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

How fish oil and milk thistle can influence genetic information associated with fatty liver disease

Date of registration: 07/29/2026 ^(mm/dd/yyyy)
Last approval date : 07/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Fentanyl for rapid sequence intubation in the emergency department

Date of registration: 07/21/2026 ^(mm/dd/yyyy)
Last approval date : 07/29/2026 ^(mm/dd/yyyy)
Last revision: 3

Study type:

Interventional

Educational video about newborn bathing: clinical trial

Date of registration: 07/29/2026 ^(mm/dd/yyyy)
Last approval date : 07/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Training of the perineal muscles combined with Hydrotherapy or Land-based exercises in women with Gestational Diabetes

Date of registration: 07/29/2026 ^(mm/dd/yyyy)
Last approval date : 07/29/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Educational videos to support the care of people with type 2 diabetes

Date of registration: 07/28/2026 ^(mm/dd/yyyy)
Last approval date : 07/28/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Short exercise sessions to improve adolescent health

Date of registration: 07/28/2026 ^(mm/dd/yyyy)
Last approval date : 07/28/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Use of Propolis in gel for Diabetic Polyneuropathy: clinical and neurophysiological evaluation in a clinical trial

Date of registration: 07/28/2026 ^(mm/dd/yyyy)
Last approval date : 07/28/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

algorithm for personalised and individualized care of apical prolapse

Date of registration: 07/28/2026 ^(mm/dd/yyyy)
Last approval date : 07/28/2026 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Username/Password

News

08/14/2026

AI Clinical Decision Support Is Everywhere. The Evidence Base Is Not.

08/14/2026 | Moe Alsumidaie | The Clinical Trial Vanguard

https://www.clinicaltrialvanguard.com/article/article-deep-dive/ai-clinical-decision-support-is-everywhere-the-evidence-base-is-not/

Imagine a site coordinator at a large academic medical center pulling up a patient’s chart in the middle of a Phase 3 oncology trial. Before she can complete her standard assessment, an AI-powered clinical decision support alert fires: elevated sepsis risk, recommended intervention, confidence score of 87%. She hesitates. The alert is generated by a vendor tool deployed hospital-wide — not validated against the specific patient population enrolled in her trial, not listed in the protocol, and not mentioned anywhere in the IND. She acts on it anyway, because the system is woven into the EHR workflow and declining the recommendation requires a three-click override that the nursing staff has been quietly skipping for months. The resulting intervention changes the patient’s concomitant medication profile. The deviation goes undocumented. The data gets locked.

That scenario is not hypothetical. According to a 2024 survey cited by Dialog Health, 71% of US hospitals now report using predictive AI integrated directly into their EHRs — up from 66% in 2023. These systems generate risk scores, flag deteriorating patients, recommend treatments, and shape clinical workflows in real time. They are present in the rooms where trials are running. And the clinical trial infrastructure built around GCP, protocol compliance, and data integrity has almost no coherent framework for handling them.

The central tension of this moment is not that AI decision support tools are unproven. Some of them work. The problem is that the evidence machine required to validate, monitor, and…

08/14/2026

What Real-World Results for an Alzheimer’s Drug Mean for Black Patients

08/14/2026 | Black Doctor

https://blackdoctor.com/lecanemab-alzheimers-drug-clinical-trial/

Sally Osmer jumped at the chance to be treated with the cutting-edge Alzheimer’s drug lecanemab.

Osmer has a family history of the disease and was diagnosed with early-stage Alzheimer’s at age 74. She didn’t notice any problems at first, but imaging and genetic testing confirmed the diagnosis.

“When I got the diagnosis, it was pretty devastating,” she said in a news release. “The prospect of having a slow decline but being physically healthy is very frightening. We were fortunate to catch it early, and I was pleased to begin treatment.”

Osmer is one of hundreds of patients who’ve shown that the new Alzheimer’s drug is as safe in the real world as it was in the clinical trials that led to its approval in July 2023, a new study says.

Some experts were concerned that lecanemab (Leqembi) would cause swelling and bleeding as it flushed toxic amyloid proteins from patients’ brains.

“There’s been a lot of fear about this medication, especially around brain swelling and bleeding,” said lead researcher Dr. Andrew Liu, an associate professor of neurology and pathology at Duke University School of Medicine in Durham, North Carolina.

Real-world results show that the drug’s safety and effectiveness among patients aligns closely to results from clinical trials, researchers said.

“What we found is that, in the real world, with careful selection and close monitoring, approximately 80 percent of patients are able to remain on lecanemab for at least one year,” Liu said in a news release. “Importantly, most treatment-related side effects resolve over time without the need for additional medications or hospitalizations.”

What…

08/14/2026
First human trials of designer protein therapies stun US neuroscientists

08/14/2026 | Laurel Oldach/Max Barnhart | c&en (Chemical&Engineering News)

https://cen.acs.org/biological-chemistry/biotechnology/human-trial-chemogenetic-brain-therapy/104/web/2026/08

Chinese researchers are testing DREADDs, a gene therapy to turn down neuronal activity, in the clinic

“Stunned silence.”

That’s how Bryan Roth of the University of North Carolina School of Medicine described the mood at a US National Institutes of Health Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative meeting in Bethesda, Maryland, this week when he told fellow attendees about at least seven clinical trials in China that are testing chemogenetic therapies in humans.

Twenty years ago, Roth developed the chemogenetic technology the trials are using, which is based on a group of proteins called “designer receptors activated by designer drugs,” or DREADDs. Designer drug is a bit of a misnomer in this case; the receptor being used in the Chinese trials responds to a small-molecule drug, clozapine, used to treat schizophrenia. But the designer receptor is much more sensitive to the drug than any human receptor, binding to it with picomolar affinity.

A researcher can introduce the gene encoding the receptor protein to a small group of neurons using a viral vector. Then, when the receptor is expressed and binds to the drug, it suppresses neuronal signaling in those cells and any brain circuits they belong to.

Dirk Trauner, a biochemist at the University of Pennsylvania who works on optogenetics, a related technology, says that DREADDs offer “a more precise knife” that, theoretically, could have reduced side effects compared with other approaches. Small molecules targeting endogenous receptors…

08/14/2026
Artificial intelligence accelerates medical device development and is already part of the daily routine for 78% of Brazilian doctors

08/14/2026 | Saúde Digital News

https://saudedigitalnews.com.br/14/08/2026/inteligencia-artificial-acelera-o-desenvolvimento-de-dispositivos-medicos-e-ja-integra-a-rotina-de-78-dos-medicos-brasileiros/

Technology is also reshaping research and development processes

While much of the debate regarding artificial intelligence in healthcare focuses on patient care, an equally significant transformation is taking place behind the scenes of innovation. Today, algorithms play a role in medical device development from the initial research stages, helping researchers design, simulate, test, and refine technologies even before the first prototypes are built. They can also anticipate risks, reduce development steps, and accelerate processes that previously relied exclusively on laboratory or clinical testing.

This transformation is already engaging regulatory bodies. In 2025, the U.S. Food and Drug Administration (FDA) published a draft guideline titled *Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations*. This was the first comprehensive guideline addressing the full development lifecycle of AI-enabled medical devices.

The publication outlines recommendations for the development, documentation, validation, and monitoring of these technologies throughout their entire lifecycle—from model conception to post-market surveillance—reflecting a new approach to evaluating devices capable of continuous evolution.

In Brazil, the Federal Council of Medicine published Resolution No. 2,454 in February 2026. This resolution regulates the use of artificial intelligence in medicine and establishes standards for AI-supported medical practices, aiming to foster…

08/14/2026
The Anti-Vaccine Movement: Politics, Disinformation, and Public Health Challenges

08/14/2026 | Isabella Tardelli Maio/Giovanna Vitor | Le Monde Diplomatique Brasil

https://diplomatique.org.br/movimento-antivacina-politica-desinformacao-e-desafios-a-saude-publica/

The narratives used to justify refusing vaccination are diverse, and the decline in vaccination coverage has raised concerns among public officials, health professionals, and society at large. What factors contribute to the strengthening of the anti-vaccine movement, considering its historical trajectory, contemporary methods of dissemination, and its impact on public perception regarding vaccination?

Introduction

According to research conducted by the Laboratory for the Study of Information Disorder and Public Policy (DesinfoPop/FGV, 2025), Brazil accounts for 40% of all anti-vaccine content circulating in Latin America and the Caribbean. This figure is particularly significant given the observed drop in vaccination coverage in recent years and prompts reflection on the factors contributing to rising vaccine hesitancy and the spread of vaccine-related disinformation. The survey indicates that, over the last decade, the country has been responsible for the circulation of more than 580,000 pieces of anti-vaccine content within online communities.

The narratives used to justify refusing vaccination vary widely. The study identified claims linking vaccines to alleged risks such as "sudden death," "poisoning," "autism," and even alterations to human DNA. Generally, this content relies on information taken out of context, misinterpretations of rare adverse events, or claims lacking scientific backing. Despite this, such content reaches a substantial audience and contributes to shaping negative perceptions regarding immunization. The mapping conducted by the researchers analyzed…

Total de Ensaios Clínicos 18764.

Existem 9599 ensaios clínicos registrados.

Existem 5178 ensaios clínicos recrutando.

Existem 69 ensaios clínicos em análise.

Existem 6221 ensaios clínicos em rascunho.

cadastre um novo usuário

notícias

sobre

painel de dados

ajuda

contato

equipe

links úteis

glossário